Clinical trials: Midazolam
- Drug or intervention Midazolam
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Depressive Disorder, Major
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
The purpose of this study is to evaluate how well JNJ-54135419 works (efficacy) in addition to comprehensive standard of care (SoC) in rapidly reducing the symptoms of major depressive disorder (MDD, a mental disorder…
- Trial name
- AVENUE (NCT07227454)
- Testing
- Esketamine, Midazolam
- Where
- 44 sites in United States, Brazil and 5 more
- Volunteers
- 258 people
- Sponsor
- Janssen Research & Development, LLC
Melanoma, Non-Small-Cell Lung Cancer
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines in people with solid tumors.
- Conditions
- Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma
- Trial name
- NCT05355701
- Testing
- PF-07799933, binimetinib, cetuximab
- Where
- 40 sites in United States, Canada and 1 more
- Volunteers
- 103 people
- Sponsor
- Pfizer
Locally Advanced Solid Tumor, Metastatic Solid Tumor
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of neladalkib (NVL-655), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced…
- Trial name
- NCT05384626
- Testing
- Neladalkib (NVL-655), Midazolam, Repaglinide
- Where
- 74 sites in United States, Australia and 13 more
- Volunteers
- 840 people
- Sponsor
- Nuvalent Inc.
Epilepsy
A Survey of Midazolam in People With Status Epilepticus
This study is a survey in Japan of midazolam oromucosal solution used to treat people with status epilepticus. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the…
- Trial name
- NCT05313308
- Testing
- Midazolam
- Where
- Japan
- Volunteers
- 50 people
- Sponsor
- Clinigen K.K.
Malignant Melanoma, Carcinoma, Non-Small-Cell Lung
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
First-in-human study to assess safety, tolerability, PK, and preliminary activity of PF-07284890 as a single agent and in combination with binimetinib in participants with BRAF V600-mutated advanced solid tumor malignancies with…
- Conditions
- Malignant Melanoma, Carcinoma, Non-Small-Cell Lung, Brain Neoplasms, Primary, Brain Neoplasms
- Trial name
- NCT04543188
- Testing
- PF-07284890, Binimetinib, Midazolam
- Where
- 45 sites in United States, Canada and 1 more
- Volunteers
- 65 people
- Sponsor
- Pfizer
Sedation
Effect & Safety of Inhaled Isoflurane vs IV Midazolam for Sedation in Mechanically Ventilated Children 3-17 Years Old
This is a study to compare safety and efficacy of inhaled isoflurane delivered by the AnaConDa-S (Anaesthetic Conserving Device (ACD)) versus intravenous midazolam for sedation in mechanically ventilated children admitted to an…
- Trial name
- IsoCOMFORT (NCT04684238)
- Testing
- Midazolam, Isoflurane
- Where
- 24 sites in France, Germany and 3 more
- Volunteers
- 94 people
- Sponsor
- Sedana Medical
Depressive Disorder, Major
Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide
The purpose of this study is to assess the efficacy of a single (first) dose of 3 fixed doses of intranasal esketamine {28 milligram (mg), 56 mg, and 84 mg} compared with psychoactive placebo (oral midazolam) in rapidly reducing…
- Trial name
- NCT03185819
- Testing
- Midazolam, Esketamine
- Where
- 51 sites in United States, Belgium and 7 more
- Volunteers
- 147 people
- Sponsor
- Janssen Research & Development, LLC
Gastrointestinal Endoscopy, Sedation
Sedation Of Adult Patients Undergoing Gastrointestinal Endoscopy: A Network Meta-analysis
The objective of this study is to compare the efficacy and safety of dexmedetomidine with other sedatives in sedation during endoscopy by analyzing the most recently published interventional trials and observational studies.
- Conditions
- Gastrointestinal Endoscopy, Sedation, Dexmedetomidine
- Trial name
- NCT03632330
- Testing
- Dexmedetomidine, Midazolam, Propofol
- Where
- South Korea
- Volunteers
- 6,963 people
- Sponsor
- Pfizer
Critical Illness
Lorazepam Sedation for Critically Ill Children
This clinical trial is being performed under the Best Pharmaceuticals for Children Act, signed into law in 2002 in order to improve pediatric labeling for off-patent drugs.
- Trial name
- NCT00109395
- Testing
- Lorazepam, Midazolam, Lorazepam CI
- Where
- United States
- Volunteers
- 179 people
- Sponsor
- The Emmes Company, LLC
Procedural Anxiety, Procedural Pain
Nebulized Lidocaine and Intranasal Midazolam for NGT Insertion in Children
Nasogastric tube (NGT) is a commonly performed procedure in the Emergency Department. Although it is not a major procedure, it is usually associated with a bad experience and cause discomfort and pain in kids.
- Trial name
- NCT04571879
- Testing
- Nebulized Lidocaine, Intranasal Midazolam
- Where
- 2 sites in Qatar
- Volunteers
- 48 people
- Sponsor
- Hamad Medical Corporation
Nervous System Diseases
Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Pediatric Patients With Status Epilepticus (Convulsive) in the Community Setting
The purpose of this study is to determine if the investigational treatment, MHOS/SHP615, is safe and effective in children with status epilepticus (SE) (convulsive) in the community setting.
- Trial name
- NCT03336450
- Testing
- SHP615, MHOS/SHP615
- Where
- 23 sites in Japan
- Volunteers
- 3 people
- Sponsor
- Shire
Nervous System Diseases
Open-label Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Children With Status Epilepticus (Convulsive) in a Healthcare Setting in Japan
The purpose of this study is to assess the efficacy, safety and pharmacokinetics of MHOS/SHP615 administered buccally in children with status epilepticus (convulsive) in a healthcare setting.
- Trial name
- NCT03336645
- Testing
- SHP615
- Where
- 23 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Shire
Epilepsy
Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters
The purpose of this study is to examine the safety and effectiveness of USL261 for the outpatient treatment of seizure clusters.
- Trial name
- ARTEMIS1 (NCT01390220)
- Testing
- USL261
- Where
- 90 sites in United States, Australia and 9 more
- Volunteers
- 292 people
- Sponsor
- UCB Biopharma S.P.R.L.
Epilepsy
A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters
The purpose of this study is to examine the long-term safety and tolerability of USL261 in the treatment of seizure clusters.
- Trial name
- NCT02161185
- Testing
- USL261
- Where
- 16 sites in United States
- Volunteers
- 7 people
- Sponsor
- UCB Biopharma S.P.R.L.
Seizures
Efficacy and Safety of Intramuscular Midazolam Compared to Buccal Midazolam in Pediatric Seizures
The goal of this study is to prove that intramuscular midazolam is more effective than buccal midazolam in cessation of seizure activity with comparable side effects.
- Trial name
- NCT02897856
- Testing
- Buccal midazolam, Intramuscular midazolam
- Where
- Qatar
- Volunteers
- 150 people
- Sponsor
- Hamad Medical Corporation
Anesthesia
Open-Label, Safety, and Efficacy Study of Dexmedetomidine in Preterm Subjects Ages ≥28 Weeks to <36 Weeks Gestational Age
The primary objective of this study is to characterize the safety, and efficacy of Dexmedetomidine (DEX) administered as an intravenous (IV) loading dose followed by a continuous IV infusion in preterm subjects, ages ≥ 28 weeks…
- Trial name
- NCT01508455
- Testing
- Dexmedetomidine, Midazolam, Fentanyl
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer
Intubated and Mechanically Ventilated Pediatric Subjects
Pharmacokinetics and Pharmacodynamics of Dexmedetomidine in Pediatrics Subjects
The objective of this study is to characterize the pharmacokinetic and pharmacodynamic profile of dexmedetomidine administered as an intravenous loading dose followed by a continuous intravenous infusion in pediatric subjects…
- Trial name
- NCT00652028
- Testing
- Dexmedetomidine, midazolam; fentanyl
- Where
- 9 sites in United States, Guatemala
- Volunteers
- 69 people
- Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer
Ultrasound, CT Scans
Open-Label, Safety Study Evaluating the Use of Dexmedetomidine in Pediatric Subjects Undergoing Procedure-Type Sedation
The objective of this study is to evaluate the safety of dexmedetomidine in a pediatric population requiring non-intubated, spontaneous breathing, moderate to deep sedation (NI-MDS) for elective diagnostic or therapeutic…
- Conditions
- Ultrasound, CT Scans, MRIs
- Trial name
- NCT01519167
- Testing
- Dexmedetomidine, Midazolam, Fentanyl
- Where
- 11 sites in United States, Puerto Rico
- Volunteers
- 91 people
- Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer
Sedation
Study Evaluating Safety and Efficacy of Dexmedetomidine (DEX) in Intubated and Mechanically Ventilated Pediatric Intensive Care Unit (PICU) Subjects
The purpose of this study is to evaluate the safety and efficacy of dexmedetomidine (DEX) in intubated and mechanically ventilated pediatric intensive care unit (PICU) subjects.
- Trial name
- NCT00875550
- Testing
- Dexmedetomidine, Midazolam, Fentanyl
- Where
- 37 sites in United States, Canada
- Volunteers
- 175 people
- Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer
Sedation
Safety, Efficacy and Pharmacokinetic Study of Dexmedetomidine in Pediatrics Ages ≥28 Weeks to ≤44 Weeks Gestational Age
The purpose of this study is to investigate the safety, efficacy and pharmacokinetics (PK) of dexmedetomidine (DEX) at 3 different dose levels in infants, ages ≥28 weeks to ≤44 weeks gestational age, administered as a loading…
- Trial name
- NCT01159262
- Testing
- Midazolam, Fentanyl/Morphine, Dexmedetomidine
- Where
- 18 sites in United States, Guatemala
- Volunteers
- 36 people
- Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer